The ODYSSEY OUTCOMES trial: Alirocumab associated with reduced ischemic events after acute coronary syndrome
1. Among patients that suffered a recent acute coronary syndrome (ACS) and had elevated levels of atherogenic lipoproteins despite intensive ...




![Combo angiotensin-neprilysin inhibitor superior to enalapril in heart failure [PARADIGM-HF trial]](https://www.2minutemedicine.com/wp-content/uploads/2014/09/Angiotensin-350x250.jpg)

